Press "Enter" to skip to content

FDA Allows for First Point-of-Care Chlamydia and Gonorrhea Test to be Used in More Near-Patient Care Settings

FDA announced the use of the Binx Health IO CT/NG Assay at point-of-care settings, such as in physician offices, community-based clinics, urgent care settings, outpatient health care facilities and other patient care settings, operating under a CLIA Waiver.

Original source:

Also Read:   Statement on the agency’s efforts to protect patients through postmarket drug safety surveillance practices